Cargando…

Lung function and microbiota diversity in cystic fibrosis

BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuthbertson, Leah, Walker, Alan W., Oliver, Anna E., Rogers, Geraint B., Rivett, Damian W., Hampton, Thomas H., Ashare, Alix, Elborn, J. Stuart, De Soyza, Anthony, Carroll, Mary P., Hoffman, Lucas R., Lanyon, Clare, Moskowitz, Samuel M., O’Toole, George A., Parkhill, Julian, Planet, Paul J., Teneback, Charlotte C., Tunney, Michael M., Zuckerman, Jonathan B., Bruce, Kenneth D., van der Gast, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114784/
https://www.ncbi.nlm.nih.gov/pubmed/32238195
http://dx.doi.org/10.1186/s40168-020-00810-3
_version_ 1783513960875556864
author Cuthbertson, Leah
Walker, Alan W.
Oliver, Anna E.
Rogers, Geraint B.
Rivett, Damian W.
Hampton, Thomas H.
Ashare, Alix
Elborn, J. Stuart
De Soyza, Anthony
Carroll, Mary P.
Hoffman, Lucas R.
Lanyon, Clare
Moskowitz, Samuel M.
O’Toole, George A.
Parkhill, Julian
Planet, Paul J.
Teneback, Charlotte C.
Tunney, Michael M.
Zuckerman, Jonathan B.
Bruce, Kenneth D.
van der Gast, Christopher J.
author_facet Cuthbertson, Leah
Walker, Alan W.
Oliver, Anna E.
Rogers, Geraint B.
Rivett, Damian W.
Hampton, Thomas H.
Ashare, Alix
Elborn, J. Stuart
De Soyza, Anthony
Carroll, Mary P.
Hoffman, Lucas R.
Lanyon, Clare
Moskowitz, Samuel M.
O’Toole, George A.
Parkhill, Julian
Planet, Paul J.
Teneback, Charlotte C.
Tunney, Michael M.
Zuckerman, Jonathan B.
Bruce, Kenneth D.
van der Gast, Christopher J.
author_sort Cuthbertson, Leah
collection PubMed
description BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches remain underpinned by classical aerobic culture-based microbiology. How to use microbiomics to direct clinical management of CF airway infections remains a crucial challenge. A pivotal step towards leveraging microbiome approaches in CF clinical care is to understand the ecology of the CF lung microbiome and identify ecological patterns of CF microbiota across a wide spectrum of lung disease. Assessing sputum samples from 299 patients attending 13 CF centres in Europe and the USA, we determined whether the emerging relationship of decreasing microbiota diversity with worsening lung function could be considered a generalised pattern of CF lung microbiota and explored its potential as an informative indicator of lung disease state in CF. RESULTS: We tested and found decreasing microbiota diversity with a reduction in lung function to be a significant ecological pattern. Moreover, the loss of diversity was accompanied by an increase in microbiota dominance. Subsequently, we stratified patients into lung disease categories of increasing disease severity to further investigate relationships between microbiota characteristics and lung function, and the factors contributing to microbiota variance. Core taxa group composition became highly conserved within the severe disease category, while the rarer satellite taxa underpinned the high variability observed in the microbiota diversity. Further, the lung microbiota of individual patient were increasingly dominated by recognised CF pathogens as lung function decreased. Conversely, other bacteria, especially obligate anaerobes, increasingly dominated in those with better lung function. Ordination analyses revealed lung function and antibiotics to be main explanators of compositional variance in the microbiota and the core and satellite taxa. Biogeography was found to influence acquisition of the rarer satellite taxa. CONCLUSIONS: Our findings demonstrate that microbiota diversity and dominance, as well as the identity of the dominant bacterial species, in combination with measures of lung function, can be used as informative indicators of disease state in CF.
format Online
Article
Text
id pubmed-7114784
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71147842020-04-07 Lung function and microbiota diversity in cystic fibrosis Cuthbertson, Leah Walker, Alan W. Oliver, Anna E. Rogers, Geraint B. Rivett, Damian W. Hampton, Thomas H. Ashare, Alix Elborn, J. Stuart De Soyza, Anthony Carroll, Mary P. Hoffman, Lucas R. Lanyon, Clare Moskowitz, Samuel M. O’Toole, George A. Parkhill, Julian Planet, Paul J. Teneback, Charlotte C. Tunney, Michael M. Zuckerman, Jonathan B. Bruce, Kenneth D. van der Gast, Christopher J. Microbiome Research BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches remain underpinned by classical aerobic culture-based microbiology. How to use microbiomics to direct clinical management of CF airway infections remains a crucial challenge. A pivotal step towards leveraging microbiome approaches in CF clinical care is to understand the ecology of the CF lung microbiome and identify ecological patterns of CF microbiota across a wide spectrum of lung disease. Assessing sputum samples from 299 patients attending 13 CF centres in Europe and the USA, we determined whether the emerging relationship of decreasing microbiota diversity with worsening lung function could be considered a generalised pattern of CF lung microbiota and explored its potential as an informative indicator of lung disease state in CF. RESULTS: We tested and found decreasing microbiota diversity with a reduction in lung function to be a significant ecological pattern. Moreover, the loss of diversity was accompanied by an increase in microbiota dominance. Subsequently, we stratified patients into lung disease categories of increasing disease severity to further investigate relationships between microbiota characteristics and lung function, and the factors contributing to microbiota variance. Core taxa group composition became highly conserved within the severe disease category, while the rarer satellite taxa underpinned the high variability observed in the microbiota diversity. Further, the lung microbiota of individual patient were increasingly dominated by recognised CF pathogens as lung function decreased. Conversely, other bacteria, especially obligate anaerobes, increasingly dominated in those with better lung function. Ordination analyses revealed lung function and antibiotics to be main explanators of compositional variance in the microbiota and the core and satellite taxa. Biogeography was found to influence acquisition of the rarer satellite taxa. CONCLUSIONS: Our findings demonstrate that microbiota diversity and dominance, as well as the identity of the dominant bacterial species, in combination with measures of lung function, can be used as informative indicators of disease state in CF. BioMed Central 2020-04-02 /pmc/articles/PMC7114784/ /pubmed/32238195 http://dx.doi.org/10.1186/s40168-020-00810-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cuthbertson, Leah
Walker, Alan W.
Oliver, Anna E.
Rogers, Geraint B.
Rivett, Damian W.
Hampton, Thomas H.
Ashare, Alix
Elborn, J. Stuart
De Soyza, Anthony
Carroll, Mary P.
Hoffman, Lucas R.
Lanyon, Clare
Moskowitz, Samuel M.
O’Toole, George A.
Parkhill, Julian
Planet, Paul J.
Teneback, Charlotte C.
Tunney, Michael M.
Zuckerman, Jonathan B.
Bruce, Kenneth D.
van der Gast, Christopher J.
Lung function and microbiota diversity in cystic fibrosis
title Lung function and microbiota diversity in cystic fibrosis
title_full Lung function and microbiota diversity in cystic fibrosis
title_fullStr Lung function and microbiota diversity in cystic fibrosis
title_full_unstemmed Lung function and microbiota diversity in cystic fibrosis
title_short Lung function and microbiota diversity in cystic fibrosis
title_sort lung function and microbiota diversity in cystic fibrosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114784/
https://www.ncbi.nlm.nih.gov/pubmed/32238195
http://dx.doi.org/10.1186/s40168-020-00810-3
work_keys_str_mv AT cuthbertsonleah lungfunctionandmicrobiotadiversityincysticfibrosis
AT walkeralanw lungfunctionandmicrobiotadiversityincysticfibrosis
AT oliverannae lungfunctionandmicrobiotadiversityincysticfibrosis
AT rogersgeraintb lungfunctionandmicrobiotadiversityincysticfibrosis
AT rivettdamianw lungfunctionandmicrobiotadiversityincysticfibrosis
AT hamptonthomash lungfunctionandmicrobiotadiversityincysticfibrosis
AT asharealix lungfunctionandmicrobiotadiversityincysticfibrosis
AT elbornjstuart lungfunctionandmicrobiotadiversityincysticfibrosis
AT desoyzaanthony lungfunctionandmicrobiotadiversityincysticfibrosis
AT carrollmaryp lungfunctionandmicrobiotadiversityincysticfibrosis
AT hoffmanlucasr lungfunctionandmicrobiotadiversityincysticfibrosis
AT lanyonclare lungfunctionandmicrobiotadiversityincysticfibrosis
AT moskowitzsamuelm lungfunctionandmicrobiotadiversityincysticfibrosis
AT otoolegeorgea lungfunctionandmicrobiotadiversityincysticfibrosis
AT parkhilljulian lungfunctionandmicrobiotadiversityincysticfibrosis
AT planetpaulj lungfunctionandmicrobiotadiversityincysticfibrosis
AT tenebackcharlottec lungfunctionandmicrobiotadiversityincysticfibrosis
AT tunneymichaelm lungfunctionandmicrobiotadiversityincysticfibrosis
AT zuckermanjonathanb lungfunctionandmicrobiotadiversityincysticfibrosis
AT brucekennethd lungfunctionandmicrobiotadiversityincysticfibrosis
AT vandergastchristopherj lungfunctionandmicrobiotadiversityincysticfibrosis